SCHEMBL31282008

SCHEMBL31282008

Cn1c(=O)n(COCC[Si](C)(C)C)c2cc(F)c(C3=CCN(C(=O)OC(C)(C)C)CC3)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK4 Q16654 1/20 0.41
TNF P01375 1/20 0.41
WDR5 P61964 2/20 0.40
GRM5 P41594 5/20 0.40
GRM1 Q13255 5/20 0.40
CDK9 P50750 3/20 0.38
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
GABRA4 P48169 1/20 0.37
GABRE P78334 1/20 0.37
GABRA6 Q16445 1/20 0.37
GABRG1 Q8N1C3 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31281722 1.00 PDK4 (0.41) PDK4TNFWDR5GRM5GRM1
SCHEMBL30289455 0.86 BRD4 (0.43) PDK4GRM5GRM1GABRPGABRD
SCHEMBL31314092 0.83 PDK4 (0.50) PDK4GRM5GRM1GABRPGABRD
SCHEMBL31433997 0.81 TNF (0.44) PDK4TNFWDR5GRM5GRM1
SCHEMBL31433915 0.79 TNF (0.45) PDK4TNFWDR5GRM5GRM1
SCHEMBL31282210 0.77 PIK3CA (0.36) SCN9A
SCHEMBL34468854 0.77 GRM1 (0.46) PDK4GRM5GRM1CDK9HTR6
SCHEMBL31281971 0.76 PIK3CA (0.35) SCN9A
SCHEMBL31282751 0.76 PIK3CA (0.37) SCN9A
SCHEMBL25305978 0.75 GRM1 (0.47) PDK4GRM5GRM1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4731309-A1 KRAS PROTEOLYSIS TARGETING CHIMERAS Paq Therapeutics Inc. (US) 2026-04-29 EP disclosed
US-12599672-B2 KRAS proteolysis targeting chimeras PAQ Therapeutics Inc. (US) 2026-04-14 US disclosed
US-20250144225-A1 KRAS Proteolysis Targeting Chimeras PAQ Therapeutics Inc. (US) 2025-05-08 US disclosed
WO-2025076044-A1 KRAS PROTEOLYSIS TARGETING CHIMERAS PAQ Therapeutics Inc. (US) 2025-04-10 WO disclosed
WO-2024263586-A1 KRAS PROTEOLYSIS TARGETING CHIMERAS PAQ Therapeutics Inc. (US) 2024-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12599672-B2 KRAS proteolysis targeting chimeras KRAS, HRAS, NRAS PDK4 4447/4885TNF 4514/4885WDR5 1447/4885
US-20250144225-A1 KRAS Proteolysis Targeting Chimeras KRAS, HRAS, NRAS PDK4 4191/4885TNF 3762/4885WDR5 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.